Last reviewed · How we verify
Dendritic Cell Tumor Fusion
At a glance
| Generic name | Dendritic Cell Tumor Fusion |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE2)
- Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (PHASE1)
- Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (PHASE1, PHASE2)
- DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission (PHASE2)
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM (PHASE1)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma (PHASE1, PHASE2)
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dendritic Cell Tumor Fusion CI brief — competitive landscape report
- Dendritic Cell Tumor Fusion updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI